Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner.
Better Models Won’t Fix Pharma’s AI Problem — Better Terminology Will
The bottleneck in AI-enabled real-world data analysis is not computation, model architecture, or training data volume. It is the semantic layer over which the AI is trying to reason – the place where precise clinical meaning lives.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
AI in Drug Development is Not a Data Problem — It’s An Evidence Problem
Drug development isn't limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence.
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
QuantHealth raised $45 million in Series B funding to expand its AI platform, which simulates clinical trials before they run and predicts patient outcomes for pharma companies. The startup is aiming to cut the industry's 90% trial failure rate and speed up the timelines for effective drugs to reach the market.
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company's cancer drug pipeline.
The AI Drug Discovery Race Is Heating Up, Not In the Way You Think
We should ask a more nuanced question than "does AI work in drug discovery." Rather, we should ask which approaches are about to be proven, and which are about to be exposed, because the field is several bets, and they are not equally sound.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
AI Can Accelerate Discovery — Development Still Decides What Advances
AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions.
AI in Drug Discovery: Surveying the Breadth of the Challenges
AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are tall orders. The companies that will benefit most are those that stay grounded, set realistic expectations, and keep experienced scientists at the center of decisions that require genuine creativity and judgment.
AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready?
More therapeutic options times more data per option times the same number of clinical hours equals something that breaks. The practices that will thrive when the next wave of longevity therapeutics arrives are the ones that have already solved this.
Valo Health CEO: We Don’t Want Investors To Drive the Science
Brian Alexander feels the current system of drug development is shaped by biotech investor expectations. Valo Health is eschewing that path.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery
Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.
Nvidia Deepens Push Into Drug Discovery Via New Partnerships with Lilly, Thermo Fisher & More
At JPM, Nvidia unveiled partnerships with Eli Lilly, Thermo Fisher and others that show how the chipmaker is pushing its AI beyond models and into the core infrastructure of drug discovery and research labs. The moves highlight Nvidia’s ambitions to become a foundational technology provider for the pharma industry.
For Merck, AI Puts Humans In the “Right Room”
The healthcare industry is contending with a difficult question: how to properly wield AI without taking on too much risk? Inherent in this battle is the role of humans. Here's how Merck's chief data officer is viewing AI.
The AI Drug Discovery Boom Is Coming. We Are Not Ready.
The real change with AI will happen not when everyone adopts the technology, which is happening quickly, but when these AIs can actually communicate and coordinate with one another.
AI’s Next Act: New Medicines
We may be on the eve of the next breakthrough: a new combination of “old” algorithms that promises to radically accelerate the discovery and development of new medicines.